Treatment of resistant enterococcal urinary tract infections

Current Infectious Disease Reports

Volumn 12, Issue 6, 2010, Pages 455-464

  Swaminathan, Subramanian ^a,b   Alangaden, George J ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Enterococcus; Resistance; Urinary tract infection; Vancomycin resistant Enterococcus

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FOSFOMYCIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LINEZOLID; NITROFURANTOIN; ORITAVANCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIURIA; CATHETER REMOVAL; CLINICAL TRIAL; COMORBIDITY; CYSTITIS; DRUG POTENTIATION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; HOSPITAL PATIENT; HUMAN; INDWELLING CATHETER; MULTIDRUG RESISTANCE; NONHUMAN; PYELONEPHRITIS; REVIEW; SINGLE DRUG DOSE; URINARY CATHETER; URINARY TRACT INFECTION; URINE CULTURE;

EID: 77958193834     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0138-8     Document Type: Review

References (71)

1. AI Hidron JR Edwards J Patel, et al. 2008 Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 Infect Control Hosp Epidemiol 29 996 1011 10.1086/591861 18947320
2. K Fisher C Phillips 2009 The ecology, epidemiology and virulence of Enterococcus Microbiology 155 1749 1757 1:CAS:528:DC%2BD1MXotVaqsL8%3D 10.1099/mic.0.026385-0 19383684
3. RJ Willems MJ Bonten 2007 Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity Curr Opin Infect Dis 20 384 390 1:CAS:528:DC%2BD2sXntlWqur4%3D 10.1097/QCO.0b013e32818be63d 17609597 (Pubitemid 47026235)
4. WJ Martone 1998 Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 19 539 545 1:STN:280:DyaK1cvivFSiuw%3D%3D 10.1086/647870 9758052
5. MJ Bonten R Willems RA Weinstein 2001 Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 1 314 325 1:CAS:528:DC%2BD38XisFShtw%3D%3D 10.1016/S1473-3099(01)00145-1 11871804 (Pubitemid 33586612)
6. GM Bearman RP Wenzel 2005 Bacteremias: a leading cause of death Arch Med Res 36 646 659 10.1016/j.arcmed.2005.02.005 16216646 (Pubitemid 41436234)
7. BE Murray 1990 The life and times of the enterococcus Clin Microbiol Rev. 3 46 65 1:STN:280:DyaK3c7isVWktQ%3D%3D 2404568
8. TL Hodges S Zighelboim-Daum GM Eliopoulos, et al. 1992 Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens Antimicrob Agents Chemother 36 121 125 1:CAS:528: DyaK38XlsFCnsA%3D%3D 1590676
9. BE Murray 2000 Vancomycin resistant enterococcal infections New Engl J Med 324 710 712
10. S Ono T Muratani T Matsumoto 2005 Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis Antimicrob Agents Chemother 49 2954 2958 1:CAS:528:DC%2BD2MXlvFSlsLY%3D 10.1128/AAC.49.7.2954-2958.2005 15980374 (Pubitemid 40917616)
11. T Rybkine JL Mainardi W Sougakoff, et al. 1998 : Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance J Infect Dis 178 159 163 1:CAS:528:DyaK1cXksVSlt7g%3D 9652435
12. S Chang DM Sievert JC Hageman, et al. 2003 Vancomycin-Resistant Staphylococcus aureus Investigative Team: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene N Engl J Med 348 1342 1347 10.1056/NEJMoa025025 12672861 (Pubitemid 36384101)
13. DK Warren A Nitin C Hill, et al. 2004 Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit Infect Control Hosp Epidemiol 25 99 104 10.1086/502357 14994932 (Pubitemid 38252336)
14. GG Zhanel NM Laing KA Nichol, et al. 2003 Antibiotic activity against UTI isolates of VRE: results from the 2002 NAVRESS J Antimicrob Chemother 53 382 388 10.1093/jac/dkg352 (Pubitemid 37120716)
15. MJ Bonten S Slaughter AW Ambergen, et al. 1998 The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable Arch Intern Med 158 1127 1132 1:STN:280:DyaK1c3ms1yhsA%3D%3D 10.1001/archinte.158.10.1127 9605785 (Pubitemid 28242318)
16. G Młynarczyk W Grzybowska A Młynarczyk, et al. 2007 Significant increase in the isolation of glycopeptide-resistant enterococci from patients hospitalized in the transplant surgery ward in 2004-2005 Transplant Proc 39 2883 2885 10.1016/j.transproceed.2007.08.045 18022008 (Pubitemid 350088075)
17. LS Chavers SA Moser WH Benjamin, et al. 2003 Vancomycin-resistant enterococci: 15 years and counting J Hosp Infect 53 159 171 1:STN:280: DC%2BD3s7htVyqtw%3D%3D 10.1053/jhin.2002.1375 12623315 (Pubitemid 38002049)
18. GM Lucas N Lechtzin DW Puryear, et al. 1998 Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes Clin Infect Dis 26 1127 1133 1:STN:280:DyaK1c3lvFGhuw%3D%3D 10.1086/520311 9597241
19. R Patel SL Allen JM Manahan, et al. 2001 Natural history of vancomycin resistant enterococcal colonization in liver and kidney transplant recipients Liver Transplantation 7 27 31 1:STN:280:DC%2BD3M7islequw%3D%3D 10.1053/jlts.2001.20784 11150418 (Pubitemid 32060910)
20. KV Singh SR Nallapareddy BE Murray 2007 Importance of the ebp (endocarditis and biofilm-associated pilus) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection J Infect Dis 195 1671 1677 1:CAS:528:DC%2BD2sXms1Ogt70%3D 10.1086/517524 17471437 (Pubitemid 46799225)
21. D Kapur D Dorsky JM Feingold, et al. 2000 Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation Bone Marrow Transplant 25 147 152 1:STN:280:DC%2BD3c7jvFegsA%3D%3D 10.1038/sj.bmt.1702123 10673672
22. Y-B Se H-J Chun H-J Yi, et al. 2009 Incidence and risk factors of infection caused by vancomycin-resistant enterococcus colonization in neurosurgical intensive care unit patients J Korean Neurosurg Soc 46 123 129 10.3340/jkns.2009.46.2.123 19763214
23. R Patel SL Allen JM Manahan, et al. 2001 Natural history of vancomycinresistant enterococcal colonization in liver and kidney transplant recipients Liver Transplant 7 27 31 1:STN:280:DC%2BD3M7islequw%3D%3D 10.1053/jlts.2001.20784 (Pubitemid 32060910)
24. Horan TC, White JW, Jarvis WR, et al.: Nosocomial infection surveillance, 1984. MMWR Morb Mortal Wkly Rep 1986, 35(1SS):17SS-29SS.
25. A Fleenor-Ford MK Hayden RA Weinstein 1999 Vancomycin-resistant enterococci: implications for surgeons Surgery 125 121 125 1:STN:280: DyaK1M7ltVyjtg%3D%3D 10.1067/msy.2099.94937 10026742
26. TM Hooten SF Bradley DD Cardenas, et al. 2010 Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America Clin Infect Dis 50 625 663
27. DK Shay SA Maloney M Montecalvo, et al. 1995 Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections J Infect Dis 172 993 1000 1:STN:280:DyaK28%2FivFeltA%3D%3D 7561221
28. GJ Alangaden R Thyagarajan SA Gruber, et al. 2006 Infectious complications after kidney transplantation: current epidemiology and associated risk factors Clin Transplant 20 401 409 10.1111/j.1399-0012.2006.00519.x 16842513 (Pubitemid 43983815)
29. AHM Wong RP Wenzel MB Edmond 2000 Epidemiology of bacteriuria caused by vancomycin-resistant enterococci-a retrospective study Am J Infect Control 28 277 281 1:STN:280:DC%2BD3cvosFSgsw%3D%3D 10.1067/mic.2000.106904 10926703 (Pubitemid 30626798)
30. MB Edmond JF Ober DL Weinbaum, et al. 1995 Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection Clin Infect Dis 20 1126 1133 1:STN:280:DyaK2MzksFaktg%3D%3D 7619987
31. JW Chow 2000 Aminoglycoside resistance in enterococci Clin Infect Dis 31 586 589 1:CAS:528:DC%2BD3cXnsVKqu70%3D 10.1086/313949 10987725 (Pubitemid 32289595)
32. JL Mainardi L Gutmann JF Acar FW Goldstein 1995 Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis Antimicrob Agents Chemother 39 1984 1987 1:CAS:528:DyaK2MXnvVygsb0%3D 8540703
33. J Gavalda O Len JM Miro, et al. 2007 Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone Ann Intern Med 8 574 579
34. CM Brandt MS Rouse NW Laue, et al. 1996 Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents J Infect Dis 173 909 913 1:CAS:528:DyaK28XisVCitb4%3D 8603970
35. JW Warren E Abrutyn JR Hebel, et al. 1999 Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women Clin Infect Dis 29 745 758 1:CAS:528:DyaK1MXnsVWhtLY%3D 10.1086/520427 10589881
36. Macrobid (nitrofurantoin monohydrate/macrocrystals) capsules [prescribing information]. Cincinnati, OH: Procter & Gamble Pharmaceuticals; 2009. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020064s019lbl.pdf. Accessed August 2010.
37. SS Patel JA Balfour HM Bryson 1997 Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections Drugs 53 637 656 1:CAS:528:DyaK2sXisFGgurs%3D 10.2165/00003495- 199753040-00007 9098664
38. ME Falagas SK Vouloumanou AG Togias, et al. 2010 Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials J Antimicrob Chemother 65 1862 1877 1:CAS:528: DC%2BC3cXhtVansbvI 10.1093/jac/dkq237 20587612
39. PC Fuchs AL Barry SD Brown 1999 Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods J Antimicrob Chemother 43 137 140 1:CAS:528:DyaK1MXhtFGktr8%3D 10.1093/jac/43.1.137 10381112 (Pubitemid 29045943)
40. M Bonadio M Meini E Tagliaferri, et al. 2000 Enterococcal glycopeptide resistance at an Italian teaching hospital J Antimicrob Chemother 46 129 131 1:CAS:528:DC%2BD3cXlsFaktL0%3D 10.1093/jac/46.1.129 10882702
41. MB Perri E Hershberger M Ionescu, et al. 2002 In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin Diagn Microbiol Infect Dis 42 269 271 1:CAS:528:DC%2BD38Xjtl2ns70%3D 10.1016/S0732-8893(02)00370-X 12007445 (Pubitemid 34455018)
42. NK Shrestha JD Chua MJ Tuohy, et al. 2003 Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin Scand J Infect Dis 35 12 14 1:CAS:528:DC%2BD3sXitlegsLs%3D 10.1080/ 0036554021000026985 12685877 (Pubitemid 36336360)
43. F Cilli H Pullukcu S Aydemir, et al. 2008 In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates Int J Antimicrob Agents 31 297 298 1:CAS:528:DC%2BD1cXitVOku7o%3D 10.1016/j.ijantimicag.2007.11.003 18180144
44. S Maraki G Samonis PI Rafailidis, et al. 2009 Susceptibility of urinary tract bacteria to fosfomycin Antimicrob Agents Chemother 53 4508 4510 1:CAS:528:DC%2BD1MXht1KkurnJ 10.1128/AAC.00721-09 19687248
45. NK Shrestha D Amuh MP Goldman, et al. 2000 Treatment of a complicated vancomycin-resistant enterococcal urinary tract infection with fosfomycin Infect Dis Clin Pract 9 368 371 10.1097/00019048-200009090-00004
46. ME Falagas KP Giannopoulou GN Kokolakis PI Rafailidis 2008 Fosfomycin: use beyond urinary tract and gastrointestinal infections Clin Infect Dis 46 1069 1077 10.1086/527442 18444827 (Pubitemid 351589875)
47. KG Naber DM Allin L Clarysse, et al. 2004 Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections Int J Antimicrob Agents 23 596 605 1:CAS:528:DC%2BD2cXkvVCru7o%3D 10.1016/j.ijantimicag.2003.12.017 15194131 (Pubitemid 38759676)
48. KG Naber A Bartnicki W Bischoff, et al. 2004 Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections Int J Antimicrob Agents 23 Suppl 1 S41 S53 1:CAS:528: DC%2BD2cXisVehtLo%3D 10.1016/j.ijantimicag.2003.09.002 15037328 (Pubitemid 38376049)
49. PK Linden 2002 Treatment options for vancomycin-resistant enterococcal infections Drugs 62 425 441 1:CAS:528:DC%2BD38XisFOlt7c%3D 10.2165/00003495- 200262030-00002 11827558
50. AH Norris JP Reilly PH Edelstein, et al. 1995 Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections Clin Infect Dis 20 1137 1144 1:STN:280:DyaK2MzksFaktA%3D%3D 7619989
51. E Lautenbach MG Schuster WB Biler, et al. 1998 The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus Clin Infect Dis 27 1259 1265 1:CAS:528:DyaK1cXnsFeksrk%3D 10.1086/515002 9827280
52. PK Linden RC Moellering Jr CA Wood, et al. 2001 Treatment of vancomycin-resistant Enterococcus faecium infections with quinipristin/ dalfopristin Clin Infect Dis 33 1816 1823 1:CAS:528:DC%2BD3MXpt1Kjt7o%3D 10.1086/323899 11668430 (Pubitemid 33105119)
53. CA Arias GA Contreras BE Murray 2010 Management of multidrug-resistant enterococcal infections Clin Microbiol Infect 16 555 562 1:CAS:528: DC%2BC3cXot1GmsrY%3D 10.1111/j.1469-0691.2009.02831.x 20569266
54. K Shea E Hilburger A Baroco E Oldfield 2008 Successful treatment of vancomycin-resistant enterococcus faecium pyelonephritis with daptomycin during pregnancy Ann Pharmacother 42 722 725 1:CAS:528:DC%2BD1cXmt1antLs%3D 10.1345/aph.1K561 18349306 (Pubitemid 351619946)
55. FM Wagenlehner S Wydra H Onda, et al. 2003 Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose Antimicrob Agents Chemother 47 3789 3794 1:CAS:528: DC%2BD3sXpsV2ntbs%3D 10.1128/AAC.47.12.3789-3794.2003 14638484 (Pubitemid 37484990)
56. MC Birmingham CR Rayner AK Meagher, et al. 2003 Linezolid for the treatment of multidrug-resistant, gram positive infections: experience from a compassionate-use program Clin Infect Dis 2 159 168 10.1086/345744 (Pubitemid 36143412)
57. JM Pogue DL Paterson AW Pasculle BA Potoski 2007 Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus Infect Control Hosp Epidemiol 28 1382 1388 10.1086/523276 17994519 (Pubitemid 351412088)
58. BI Eisenstein 2004 Lipopeptides, focusing on daptomycin, for the treatment of gram-positive infections Expert Opin Investig Drugs 13 1159 1169 1:CAS:528:DC%2BD2cXmvFSmsrc%3D 10.1517/13543784.13.9.1159 15330747 (Pubitemid 39242739)
59. FM Wagenlehner KG Naber 2004 New drugs for gram-positive uropathogens Int J Antimicrob Agents 24 Suppl 1 S39 S43 10.1016/j.ijantimicag.2004.02.002 15364305 (Pubitemid 39208859)
60. FL Sapico VJ Ginunas HN Canawati JZ Montgomerie 1988 LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model Antimicrob Agents Chemother 32 81 83 1:CAS:528: DyaL1cXmvVertA%3D%3D 2831816
61. CA Arias HA Torres KV Singh, et al. 2007 Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster Clin Infect Dis 10 1343 1346 10.1086/522656 (Pubitemid 351411911)
62. MP Stevens MB Edmond 2005 Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature Clin Infect Dis 8 1134 1142 10.1086/444459 (Pubitemid 41429476)
63. KG Naber BI Eisenstein FP Tally 2004 Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria Infect Dis Clin Pract 12 322 327 10.1097/01.idc.0000144898.12957.eb (Pubitemid 39507293)
64. L Fisher D North 2009 Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections Int J Antimicrob Agent 33 493 494 1:CAS:528:DC%2BD1MXjvVWqtbc%3D 10.1016/j. ijantimicag.2008.11.003
65. Tygacil [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; 2010. Available at http://www.wyeth.com/content/showlabeling. asp?id=491. Accessed August 2010.
66. DJ Hoban SK Bouchillon BM Johnson, et al. 2005 Tigecycline Evaluation and Surveillance Trial (TEST Program) Group: In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004) Diagn Microbiol Infect Dis 52 215 227 1:CAS:528:DC%2BD2MXos1ait7o%3D 10.1016/j.diagmicrobio.2005.06.001 16105567 (Pubitemid 41133548)
67. EJ Ellis-Grosse T Babinchak N Dartois, et al. 2005 Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam Clin Infect Dis 41 Suppl 5 S341 S53 1:CAS:528:DC%2BD2MXhtVWmsrzJ 10.1086/431675 16080072 (Pubitemid 41170381)
68. T Babinchak E Ellis-Grosse N Dartois, et al. 2005 Tigecycline 301 Study Group; Tigecycline 306 Study Group: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data Clin Infect Dis 41 Suppl 5 S354 S67 1:CAS:528: DC%2BD2MXhtVWmsrrN 10.1086/431676 16080073 (Pubitemid 41170382)
69. DE Nix KR Matthias 2010 Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation J Antimicrob Chemother 65 1311 1312 1:CAS:528:DC%2BC3cXmtFOhuro%3D 10.1093/jac/dkq116 20378673
70. Vibativ (telavancin) for injection [prescribing information]. South San Francisco, CA: Astellas Pharma; 2009. Available at http://www.vibativ.com. Accessed August 2010.
71. A Lefort A Saleh-Mghir L Garry, et al. 2000 Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis Antimicrob Agents Chemother 44 3017 3021 1:CAS:528:DC%2BD3cXnvVSju7s%3D 10.1128/AAC.44.11.3017- 3021.2000 11036016